DermTech (NASDAQ:DMTK – Get Rating) and Viridian Therapeutics (NASDAQ:VRDN – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

75.1% of DermTech shares are held by institutional investors. 3.6% of DermTech shares are held by company insiders. Comparatively, 4.5% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares DermTech and Viridian Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares DermTech and Viridian Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

DermTech has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for DermTech and Viridian Therapeutics, as provided by MarketBeat.com.

DermTech presently has a consensus target price of $19.33, indicating a potential upside of 238.59%. Viridian Therapeutics has a consensus target price of $40.20, indicating a potential upside of 70.48%. Given DermTech's higher possible upside, equities research analysts plainly believe DermTech is more favorable than Viridian Therapeutics.

Summary

DermTech beats Viridian Therapeutics on 10 of the 14 factors compared between the two stocks.

About DermTech

(Get Rating)

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.